Therapeutic Targets in Chordoma
Drugs and other therapeutic interventions often exert their effects by binding to specific gene or protein targets within cells and altering the actions of those targets to treat disease. The Therapeutic Target Dashboard summarizes published evidence pointing to altered genes, proteins, and signaling pathways as potential therapeutic targets for chordoma.
Chordoma researchers have taken various approaches to understand the roles these targets play in chordoma, and they’ve generated numerous types of evidence. Click the name of a target gene, protein, or pathway in the first column to see a summary of their findings. Click a cell in one of the evidence columns to see the results of a certain type of study, described below. Click a cell in the final column to see a list of clinical trials that are relevant to a target and are open to chordoma patients.
- Molecular Evidence is generated by basic research studies that search for genetic variants and chromosomal abnormalities, discover differences in gene or protein expression patterns, or detect activation or inactivation of various signaling pathways. These studies help not only to identify a therapeutic target but also to understand how it behaves in chordoma and how it could be manipulated to treat the disease.
- Preclinical Evidence is generated when a drug or therapeutic agent is tested in a model system, whether in-vitro (in a chordoma cell line) or in-vivo (in a living organism, such as a mouse xenograft). Preclinical studies can help researchers to identify drugs most likely to be effective in chordoma patients, and provide rationale for clinical trials.
- Clinical Evidence is generated by case reports and clinical trials in which chordoma patients have been treated with a therapeutic agent relevant to the target of interest.